# A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency

> **NCT02476916** · PHASE2 · COMPLETED · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Pyruvate Kinase Deficiency

## Interventions

- **DRUG:** AG-348

## Key facts

- **NCT ID:** NCT02476916
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-26
- **Primary completion:** 2017-05-08
- **Final completion:** 2025-04-02
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02476916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02476916, "A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT02476916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*